Selected Publications

H. Newman, Y. Li, H. Liu, R.M. Myers, V. Tam, A. DiNofia, L. Wray, S.R. Rheingold, C. Callahan, C. White, D. Baniewicz, L.E. Winestone, S. Kaduake, C. Diorio, C.H. June, K. Getz, R. Aplenc, D.T. Teachey, S.L. Maude, S.A. Grupp, K. Bona, A. Barz Leahy.: Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. Blood 141(6): 609-619, Feb 2023.

R.M. Myers, A.M. DiNofia, Y. Li, C. Diorio, R. Aplenc, D. Baniewicz, J.L. Brogdon, C. Callahan, B. Engels, J.A. Fraietta, V. Gonzalez, E. Iannone, A.B. Leahy, H. Liu, S.E. McClory, S.R. Rheingold, L. Shinehouse, G. Wertheim, L. Wray, N.V. Fray, S. L. Maude, S.A. Grupp.: CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells. Oral Presentation at American Society of Hematology Meeting and Exposition. New Orleans, LA 2023.

C. Diorio, R. Shraim, R.M. Myers, E.M. Behrens, S. Canna, H. Bassiri, R. Aplenc, C. Burudpakdee, F. Chen, A.M. DiNofia, S. Gill, V.E. Gonzalez, M.P. Lambert, A. Barz Leahy, B.L. Levine, R.B. Lindell, S.L. Maude, J.J. Melenhorst, H. Newman, J. Perazzelli, A.E. Seif, S.F. Lacey, C.H. June, D. M. Barrett, S. A. Grupp, D.T. Teachey.: Comprehensive serum proteome profiling of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome patients with B-Cell ALL receiving CART19. Clinical Cancer Research 28(17): 3804-3813, Sept 2022.

E.M. Hsieh, R.M. Myers, B. Yates, C. Annesley, S. John, A. Taraseviciute, S.M. Steinberg, J. Sheppard, P. Chung, L. Chen, D.W. Lee, A. DiNofia, S.A. Grupp, M.R. Verneris, T.W. Laetsch, B. Bhojwani, P.A. Brown, M.A. Pulsipher, S.R. Rheingold, R.A. Gardner, L. Gore, N.N. Shah, A.J. Lamble.: Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy. Blood Advances. 6(17): 5222-5226, Sept 2022.

A. Lamble, R.M. Myers, A. Taraseviciute, S. John, B. Yates, S.M. Steinberg, J.D. Sheppard, A.E. Kovach, B.L. Wood, M.J. Borowitz, M. Stetler-Stevenson, C.M. Yuan, V. Pillai, T. Foley, P. Chung, L. Chen, D.W. Lee, C. Annesley. A. DiNofia, S.A. Grupp, M.R. Verneris, L. Gore, T.W. Laetsch, D. Bhojwani, P.A. Brown, M.A. Pulsipher, S.R. Rheingold, R.A. Gardner, N.N. Shah: Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Advances 7(4): 575-585, April 2022.

RM Myers, A Taraseviciute, SM Steinberg, AJ Lamble, J Sheppard, B Yates, AE Kovach, B Wood, MJ Borowitz, M Stetler-Stevenson, CM Yuan, V Pillai, T Foley, P Chung, L Chen, DW Lee, C Annesley, AM DiNofia, SA Grupp, S John, D Bhojwani, PA Brown, TW Laetsch, L Gore, RA Gardner, SR Rheingold, MA Pulsipher, NN Shah: Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. Journal of Clinical Oncology 40(9): 932-944, March 2022.

KO McNerney, AM DiNofia, DT Teachey, SA Grupp, SL Maude: Potential Role of IFN inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy. Blood Cancer Discovery 3(2): 90-94, March 2022.

A Barz Leahy, KJ Devine, Y Li, H Liu, RM Myers, AM DiNofia, L Wray, SR Rheingold, C Callahan, D Baniewicz, M Patino, H Newman, SP Hunger, SA Grupp, DM Barrett, SL Maude: Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Blood 139(14): 2173-2185, December 2021.

BJ Lerman, Y Li, H Liu, RM Myers, K Devine, C Callahan, D Baniewicz, S Kaduake, AM DiNofia, SR Rheingold, L Wray, R Aplenc, SA Grupp, SL Maude, A Barz Leahy: Completed versus incomplete hematologic recovery after CAR T cell therapy: implications for relapse free survival and overall survival in pediatric and young adult patients with relapse/refractory B-ALL. Poster Presentation at American Society of Hematology Meeting and Exposition. Atlanta, GA Dec 2021.

AB Leahy, H Newman, Y Li, H Liu, R Myers, AM DiNofia, JG Dolan, C Callahan, D Baniewicz, K Devine, L Wray, R Aplenc, CH June, SA Grupp, SR Rheingold, SL Maude: CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukemia; a post-hoc analysis of pool data from five clinical trials. The Lancet Haematology 8(10): e711-e722, October 2021.